[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Ozmosi [@OzmosiHealth](/creator/twitter/OzmosiHealth) on x 2630 followers Created: 2025-07-23 02:33:49 UTC $ABVX, PARIS:ABVX, PARIS:FR Abivax reports successful Phase X trial results for ABTECT 8-week induction studies on Obefazimod, a unique oral miR-124 enhancer for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH  XXX engagements  **Related Topics** [$pph](/topic/$pph) [$xph](/topic/$xph) [$ibb](/topic/$ibb) [$xbi](/topic/$xbi) [more info](/topic/more-info) [$abvx](/topic/$abvx) [Post Link](https://x.com/OzmosiHealth/status/1947847592425230474)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Ozmosi @OzmosiHealth on x 2630 followers
Created: 2025-07-23 02:33:49 UTC
$ABVX, PARIS:ABVX, PARIS:FR Abivax reports successful Phase X trial results for ABTECT 8-week induction studies on Obefazimod, a unique oral miR-124 enhancer for ulcerative colitis.
More Info: $XBI $IBB $XPH $PPH
XXX engagements
/post/tweet::1947847592425230474